Medicare drug pricing
CMS sets a temporary floor for small biotech drugs
The proposal would apply only to selected drugs entering Medicare’s price negotiation process in 2029 or 2030, with the floor set at 66% of each drug’s 2021 average non-FAMP.
CMS is proposing a narrow Medicare drug-price rule for certain small-biotech medicines. It would create a temporary floor for selected drugs whose first price-applicability year falls in 2029 or 2030, limiting how low the negotiation can start.
- CMS is proposing a temporary floor for some small-biotech drugs.
- The rule would apply only to selected drugs that meet the statutory test.
- The floor would cover drugs whose first price year is 2029 or 2030.
- CMS says the floor would equal 66 percent of the drug’s 2021 average non-FAMP.
- The change would affect a narrow slice of Medicare’s drug-price negotiation program.
Federal Medicare officials are proposing a temporary price floor for a small group of biotech drugs. The Centers for Medicare & Medicaid Services, or CMS, says the rule would apply inside Medicare’s drug-price negotiation program and would affect only selected drugs that meet the small-biotech test and first enter the price-setting process in 2029 or 2030.
In plain terms, CMS would not be changing the whole program. It would create a special starting point for a narrow set of medicines in the federal Medicare system.
Which drugs would be covered
The proposal is limited to selected drugs that are qualifying single-source drugs and that meet the statutory requirements to be treated as Small Biotech Drugs. Timing also matters. The first initial price applicability year has to fall in 2029 or 2030.
That makes the change a targeted carve-out, not a broad rewrite. It would sit alongside Medicare’s wider negotiation rules rather than replace them.
What the floor would do
A price floor sets the lowest point Medicare can start from in this part of the negotiation process. For the drugs covered here, that floor would be equal to 66 percent of the drug’s 2021 average non-FAMP, according to the proposal.
That matters for both sides of the table. Drug makers would know the starting point is not open-ended, and Medicare would have a defined floor as it works through prices for those selected medicines.
Why it matters
The proposal gives small-biotech drugs their own rule for a limited period, instead of treating them exactly like every other medicine in the negotiation program. For patients, the change could shape how Medicare prices certain treatments. For manufacturers, it could affect how much room there is for the first round of negotiations.
Because the rule is tied to specific years and a specific category of drugs, its reach is narrow. But it could still matter for a small set of medicines that land in that window.